The findings in our data show the 70–75-year window as a critical period of vulnerability for APOE4-related effects in MCI and AD, consistent with previous reports of age-dependent risk patterns (Wang J. et al., 2022; Eyamu et al., 2025). This evidence concerns the gene APOE and Alzheimer disease.